Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Change in Receivables (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Change in Receivables for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables changed N/A to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a N/A change, with the full-year FY2025 number at $28.2 million, changed N/A from a year prior.
  • Change in Receivables was $2.7 million for Q4 2025 at Soleno Therapeutics, up from $882000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.7 million in Q4 2025 to a low of $882000.0 in Q3 2025.